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Osteoporosis is more common in women than in men. The prevalence in men is not deﬁned yet; however it is becoming much
morerecognized asitsprevalenceandimpacthavebecomeexplicable.Itisestimatedthataround1%ofbonemineraldensityislost
in men every year. Studies show that secondary osteoporosis is the major cause thus, making it important to deﬁne the disorders
associated with male osteoporosis. Diabetes is a risk factor for bone fractures. In male patients with diabetes measures should be
undertaken such as encouraging exercise, assuring adequate calcium and vitamin D intake, and treating diabetic complications.
1.Introduction
Although it is the most common cause in women, primary
osteoporosis is less common in men, but it is a disease that
is being more and more recognized. Prevalence has always
been a challenge to determine, mainly because of the lack of
consensusonthedeﬁnitionofosteoporosisinmen.Withage,
menareestimatedtolosearound1%ofbonemineraldensity
per year [1, 2]. Despite that, osteoporosis in men should not
be assumed to be primary because some studies have shown
that more than 50% of osteoporosis in men has a secondary
cause [3]. The deﬁnition of secondary osteoporosis is bone
loss resulting from a speciﬁc, well-deﬁned disease. Since this
form of osteoporosis can respond to the treatment of the
underlying disease, and with the presence of many treatment
options now available, it is imperative to recognize the
disorders that are associated with male osteoporosis. More
evidence is evolving about the association between diabetes
and osteoporosis in both men and women. Both conditions
aﬀect a large proportion of men, thus, it is very important to
assess whether there is a causal relationship thatmight orient
further screening and management of male osteoporosis.
M e na n dw o m e nw i t hd i a b e t e sw e r ef o u n dt oh a v eh i g h e r
risk of fractures compared to nondiabetics [4–9]. The risk
seems to be multifactorial, with osteoporosis gaining more
and more interest recently. This association seems to be race,
sex, and type dependent.
2.Type2DM
BMD changes in males with type 2 diabetes are very contro-
versial, with both tendenciestoward higher, normal, orlower
values. In studies assessing osteoporosis in diabetic patients,
osteoporosis was deﬁned according to the WHO deﬁnition
with T-score > −1 as normal, between −1a n d−2.5 as
osteopenia,and< −2.5asosteoporosis.TheRotterdamstudy
[10] was a cross-sectional study that measured BMD at
lumbar spine and proximal femur using DXA in 243 DM
men and 2238 healthy men. It is one of the largest studies
on BMD in type 2 DM. The study showed around 3% higher
BMD at both sites in DMvs non-DM subjects that remained
signiﬁcant even after adjustment for confounders, mainly
BMI and age.
Another study showing higher BMD in diabetic men was
the EVOS study [11] that is a population-based prevalence
study evaluating the eﬀects of diabetes on bone density
(measured using DXA at lumbar spine, femoral neck and
femoral trochanter) and bone deformity prevalence in DM
menversusnon-DM.The studydemonstrated thatmenwith
DM not treated with insulin had an increase in BMD only at
the spine that was signiﬁcant even after adjustment for body
weight.
In the Health, Aging, and Body composition study [12]
by Strotmeyer et al. 323 both white (38%) and black (62%)
men with type 2 DM were evaluated. Fat mass and lean2 Journal of Osteoporosis
body mass were measured using DXA and CT. The study
reported higher BMD (4-5%) at the hip in both races that
was independent of body mass and composition, and the
results were in concordance with older studies that also
showed higher BMD in type 2 DM [13, 14].
Krakauer et al. [15] evaluated 109 diabetic patients (46
type1 and 63type2). Inthisstudy,radial bonedensity, bone
markers, and bone biopsy (in 8 patients) were assessed. It
was shown that there was lower radial bone density in both
groups relatively to nondiabetic controls, with no diﬀerence
between patients with either type of diabetes. Transiliac
bone biopsy results showed decreased bone formation and
mean adjusted apposition by 75% and 70%, respectively.
Some of these patients were followed up after 2.5 years (41
patients) and 12.5 years (35 patients) showing that bone loss
continued at an expected rate in type 1 with maintenance
of the same deﬁcit, whereas in type 2 there was a slower
than expected loss such that the initial deﬁcit was completely
corrected.
In contrast to the above studies ﬁnding higher BMD in
type 2 diabetic men, other studies showed no diﬀerence in
BMD [15–17]. In one of them, Tuominen et al. [18]s h o w e d
no signiﬁcant diﬀerence in BMD between men with type 2
diabetes and controls at the femoral neck and trochanter.
The study involved 56 patients with type 1 DM and 68
patients with type 2 DM from both sexes along with 498
non-DM controls. Similar ﬁndings were shown in a study
by Shwartz et al. [19] evaluating bone loss at the hip over
4 years (measuring BMD at baseline and at the end of 4
years) in 480 DM men and women, 439 with impaired
glucose metabolism, and 1172 healthy controls. It was found
that despite having higher baseline BMD, only diabetic
white women, but not black women nor men with DM
and impaired glucose metabolism, demonstrated signiﬁcant
bone loss.
Other studies, on the other hand, showed lower BMD in
patients with type 2 DM [20, 21]. In a cross-sectional study
[22] involving 735 type 2 DM and 3458 nondiabetic men,
BMD at the hip and spine was measured. This study showed
lower BMD at the hip and higher incidence of osteoporosis
in diabeticmen thatwas signiﬁcant evenafter adjustment for
age and BMI. BMD at the spine was signiﬁcantly higher in
diabetics when compared to controls, but when adjusted for
BMI, it became similar.
In another study by Petit et al. [23], using peripheral
quantitative CT (pQCT) this time instead of assessing BMD
byDXAtomeasure tibialand radialbonevolumetricdensity,
bone geometry, and bone strength. Bone strength was
determined by measuring estimates of bone compressive and
bending strength. Calculated bone strength index was used
as an index of bone compressive strength, and calculated
strength strain index was used as an index of bone bending
strength. It was shown that older men with type 2 DM
have bone strength that is low relative to body weight at the
cortical-rich midshaft of the radius despite no diﬀerence in
cortical bone volumetric density. This can account for the
increased risk of fractures despite higher BMD in type 2 DM
patients which might incriminate DXA as being a weak tool
to assess bone in type 2 DM males.
A conclusion is very hard to draw after all the controver-
sies shown in those studies, and to make things even more
complicated, all those trials neglected to study the cortical
bone which is a major limitation since bone is heterogenous
(cortical and trabecular) and since diabetes, as many other
endocrinological disorders such as hyperparathyroidism and
hyperthyroidism, might aﬀect cortical bone more than
trabecular bone.
In order to correct for this limitation, other studies
tried to study the BMD at the cortical bone showing that
diabetescanactuallyaﬀectboneheterogeneouslybyaﬀecting
cortical more than the trabecular bone [24, 25]. One of them
[25] was conducted on 64 diabetic and 41 healthy Japanese
men. BMD was measured using DXA at the lumbar spine,
femoral neck, and distal radius, and it showed a signiﬁcantly
lower BMD at the distal radius in type 2 DM patients
versus controls, that was even lower than their own BMD
at the spine and femur. In type 2 DM, there was a negative
correlation between BMD at the distal radius and mean
HBA1C during the past 2 years. These ﬁndings demonstrate
the importance of measuring 3 sites in patients with type 2
DM because of the possible selective cortical involvement.
S i n c ed i a b e t e si sp r e c e d e db ys ev e r a ly e a r so fp r e - d i a b e t i c
stage, it is worth to study the eﬀect of impaired fasting glu-
cose (deﬁned as fasting glucose between 100–125mg/dL) or
impaired glucose tolerance (deﬁned as a 2hr glucose level
between 140–200mg/dL post 75gr oral glucose load) on the
BMD,inordertotry toﬁnd apathophysiologybehindosteo-
p o r o s i si nd i a b e t e sa n dt ot r yt oﬁ n dw h e nd o e st h ee ﬀect on
BMD start and whether there is a way to prevent it or stop
it. Unfortunately, few studies evaluated BMD in prediabetic
men. One of them [26] compared BMD in 272 men with
prediabetes and 406 normal men. The study showed no dif-
ference in BMD between the 2 groups. However, when the
prediabetic men were divided into quartiles based on fasting
insulin and insulin levels 2hrs after-75gr glucose, it was
noted that the BMD T-score increased with the increase in
fasting insulin (P = .004). Additionally, the subjects with
the highest concentrations of fasting insulin belonged to the
groups with higher BMD T- scores (P<. 001).
3.Type1DM
As in type 2 DM, there is also some controversy as to the
association between type 1 DM and osteoporosis, but in
contrast to type 2 DM most [27–31]b u tn o ta l l[ 32, 33]
studies showed decreased BMD. In contrast to type 2 DM,
there seems to be an important gender diﬀerence with more
marked bone loss in men versus women when compared to
matched controls [27–30].
T h es a m es t u d yb yT u o m i n e ne ta l .[ 18]o nb o t ht y p e1
and type 2 DM patients of both genders, measuring BMD
using DXA at the proximal femur, revealed that among both
sexes, BMD values are signiﬁcantly lower in type 1 versus
type 2 DM or controls. The diﬀerence between type 1 DM
and controlsremained signiﬁcant in bothsexesevenafterad-
justment for age and BMI, whereas the diﬀerence between
type1andtype2remainedonlysigniﬁcantinmen.ThelatterJournal of Osteoporosis 3
diﬀerence remained unaltered after further adjustment for
durationofdiabetes,butwasslightlyreducedwhenaddition-
ally adjusted for duration of insulin treatment and dose.
In another study [28] conducted on 30 type 1 DM men
and 30 type 1 DM women versus 60 healthy controls, fol-
lowed retrospectively, it was shown that male patients with
type 1 diabetes has a signiﬁcantly lower BMD values and
lowerZ-scores atthespine andfemoralneckwhencompared
with healthy men (P<. 05). This diﬀerence remained the
same after adjustment for age. The percentages of both oste-
oporosis and osteopenia were higher in DM men when com-
pared to both normal men and diabetic women. There
was no signiﬁcant correlation between age-adjusted BMD
values, and either diabetes duration, HBA1C values or age of
onset of diabetes. Femoral neck BMD values were positively
correlated with BMI in both female groups but only in
healthy men. In conclusion, this study showed low BMD
values in type 1 DM men and showed the gender diﬀerence
on the eﬀect of diabetes on BMD where diabetic men had
lower BMD values when compared with diabetic women.
Few studies have assessed bone markers in diabetic men.
In one of them [31], both BMD (measured by DXA) and
serum bone markers (osteocalcin, C-terminal telopeptide of
type 1 collagen (CTX), leptin and osteoprotegerin (OP))
were measured in 42 adult type 1DM men and 24 non-
diabetic controls. It was shown that 40% of type 1DM
patients had osteopenia at the spine and/or hip and 7% met
criteria for osteoporosis. BMD z-score was correlated with
age, negatively correlated with CTX, and osteocalcin. Osteo-
calcin, CTX and leptin concentrations were comparable in
both groups, while OPG concentrations tended to be higher
in DM. Despite the fact that there was not an increase in
bone resorption markers in this study, this does not exclude
a previous state of increased bone resorption. This is favored
by the increase in OPG observed in this study that can be a
protective mechanism of the skeleton to compensate for the
possible previous increased bone resorption and bone loss.
In another study, where more bone markers and hor-
monal markers, especially testosterone, were measured,
Hamilton et al. [33] conducted a cross-sectional trial involv-
ing 50 type 1DM men, and 50 healthy controls, aged 30–
71 years, assessing biochemical/hormonal markers of bone
metabolism (25-hydroxy vitamin D3, PTH, CTX, osteo-
calcin, procollagen type 1 N-terminal propeptide (P1NP),
total and free serum testosterone, sex hormone-binding
globulin (SHBG), luteinizing hormone (LH), and follicule
stimulating hormone (FSH)).BMD values at forearm, spine,
and hip were recorded. It was shown, after adjustment for
age and BMI, that BMD values, T and Z-scores were lower
in DM men versus controls (P<. 048). Prevalence of oste-
oporosis and osteopenia was higher only at the spine in
DM men (P = .03). After adjusting for age and BMI, the
investigators found that BMD was not signiﬁcantly associ-
ated with HBA1C, smoking, nephropathy, retinopathy, or
neuropathy. Only higher BMD at the spine was associ-
ated with diabetes duration. On multiple linear regression
analysis, which adjusted for the natural logarithm (Ln) of
the sex hormone-binding globulin concentration, smoking
status, and alcohol consumption, it was shown that serum
alkaline phosphatase was signiﬁcantly negatively associated
withBMDat 3sites.There wasapositiveassociationbetween
Ln (free testosterone) and BMD at the forearm and a neg-
ative association between Ln (osteocalcin) and BMD at the
forearm.
In a Dutch study [34], osteopenia was found in as many
as 67% and osteoporosis was seen in as many as 14% of 21
type 1DM men compared to healthy controls. It was shown
also that osteopenia was associated with low serum IGF-1
levels and bone formation markers.
In the study that was mentioned previously, conducted
by Krakauer et al. [15], again it was shown that radial bone
density was lower in type 1DM relatively to nondiabetic
controls, butthislowBMDseemstobestableovertime,with
expected stable bone loss, according to this study.
In another study [35], trying to follow type 1DM pa-
tients over time, to study for the changes in bone density,
41 type 1DM (19 female, 22 males), mean age 9 years, were
followed for around 5 years. Two sites of the nondominant
radius were analyzed by pQCT. At the distal radius (meta-
physeal site) total and trabecular BMD and at the prox-
imal radius (diaphyseal site) total and cortical BMD, total
cross-sectional area (CSA), cortical CSA, medullary CSA,
muscle CSA, and strength strain index as measure of bone
stabilitywerecalculated.Itwasshown inthisstudythatatthe
1st evaluation, mean SD value of trabecular BMD was even
higher in type 1 diabetic patients than in controls, irrespec-
tive of age, sex, and Tanner stage. At the diaphysis, patients
with type 1 DM had signiﬁcantly reduced mean SD values
fortotal,cortical,andmedullary SCAaswell ascorticalBMD
which hadnormalized atthe2ndmeasurement. Theyounger
the patients were at the disease manifestation and at the 1st
evaluation,themore theincrease intotalCSAwas detectable.
Asaconclusion,thisstudysuggestsadefectinboneaccretion
earlyinthecourseoftype1DM,which thenameliorateswith
time.Alimitationofthisstudywasthesmall number, butthe
s t r e n g t hi su s i n gp Q C Ta sat o o lf o rb o n em e a s u r e m e n t sa n d
the 5-year followup.
Moreover, in another study [36]u s i n gb o t hp Q C Ta n d
DXA to measure bone mass and structure in 48 adolescents
with type 1 DM (26 girls and 22 boys), pQCT measurements
were performed at the distal and shaft sites of the dominant
radius and the right tibia. BMC, total cross-sectional area
and trabecular density were determined for the distal sites,
BMC, cortical density, and cortical cross-sectional area were
determined for the shaft sites. It was shown that diabetes
was associated with reduced bone mineral content (BMC)
and smaller bone cross-sectional size, with boys being more
aﬀectedthangirlswithameandeﬁcitinBMCofallmeasured
skeletal sites of >10% in boys and <5% in girls.
4. Type 1 and Type 2 DM
Because most of the studies involved a small number of
patients, in order to correct for this limitation and increase
the power, a meta-analysis [30] including 80 papers on BMD
and fracture risk in patients with type 1 and 2DM was done
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risk of fractures in both types of diabetes mellitus compared
to non-diabetes mellitus. Z-score in hip and spine was
decreased in type 1 and increased in type 2DM. A meta-
regression showed that mainly BMI was the major determi-
nant for BMD, whereas HBA1C was not linked to BMD. The
increase in fracture risk was higher and BMD was lower in
patients with complications of DM.
4.1. In Conclusion. The relationship between diabetes, both
types, and osteoporosis seems complex. Mainly because
the studies were limited by the small number, patients
werenot followed up for a long period of time, studies were
heteregenous with diﬀerent diabetes control and duration,
diﬀerent complications, which makes it hard to draw a
unique conclusion. But the trend seems to be a low BMD
in type 1DM and a high BMD in type 2DM. More studies
correcting for the mentioned limitations need to be per-
formed.
5.Pathophysiologyof AlteredBMD in
DiabeticPatients
Several hypotheses have been raised to explain the altered
BMD in diabetic patients. Although the most popular one
was the higher BMI in type 2DM that can protect from oste-
oporosis, most of the studies discussed previously corrected
for BMI, yet despite this correction there was still a higher
BMD in patients with type 2 diabetes relatively to type 1 and
healthy controls.
6.Insulinand InsulinGrowthFactors
One popular hypothesis to the eﬀect of diabetes on bone is
through insulin, acting as a bone anabolic factor. The im-
portance of this hypothesis is that it can also explain the
pathophysiology behind the diﬀerence between type 1 and
type 2 diabetic men. Insulin seems to have both direct and
indirect eﬀects on bone.
Support for a direct role of insulin in bone comes mainly
from animal studies, speciﬁcally rats, where streptozocin-
induceddiabetesledtodefectsofbonemineralization.More-
over,ratslackinginsulin receptorshadimpairedboneforma-
tion and low bone turnover [37–39]. In a recent study con-
ducted by Fulzele et al. [40], to try and directly examine the
function of insulin signaling in bone, they engineered mice
lacking insulin receptor (IR) speciﬁcally in osteoblasts. It
was shown that osteoblasts lacking IR had severely impaired
diﬀerentiation,withincreasedapoptosis.Theyshoweda79%
decreaseinthenumberofosteoblastsperboneperimeterat3
weeksofage.This ledtoadramatic impairement inpostnatal
trabecular bone acquisition. Administration of IGF-1 did
not correct for the abnormalities seen, showing the direct
eﬀect of insulin, independently of IGF-1 on the bone. A
high level of expression of insulin receptors on osteoblasts
was reported [41], and insulin binding to these receptors
led to cell proliferation, production of alkaline phosphatase,
collagen synthesis, and glucose uptake [42–45]. The eﬀect of
insulin seemsnotonlylimitedtoosteoblasts, becausein vitro
studies showed that osteoclasts as well have insulin receptors
where insulin can act to inhibit their action [46].
Human data support this hypothesis. A large study com-
prising of over 100 subjects with type 1 diabetes mellitus
showed lower IGF-1 levelsas well as bone formation markers
when compared to healthy controls [47, 48]. Moreover, low
levels of IGF-1 were found to be associated with osteopenia
in type 1 DM patients [48].
In contrast to type 1 diabetes mellitus where there is
insulin deﬁciency, in type 2 diabetes mellitus there is insulin
resistance and hyperinsulinemia which can explain the high-
er BMD in type 2 diabetes mellitus. Since the insulin resis-
tance is selective and only restricted to the eﬀect of insulin
on glucose transport [49], the high insulin levels can still act
ontheosteoblasttoincreaseBMD.Indeedsomeinvestigators
found a positive correlation between insulin levels and BMD
[50, 51] ,y e to t h e r sd i dn o t[ 52, 53].
In addition to a direct eﬀect of insulin on osteoblast and
osteoclast, insulin can indirectly act on the bone by decreas-
ing sex-hormone binding globulin [54–57] leading to higher
levels of free estrogen and testosterone, acting positively
on the bone to increase BMD [58]. It can act indirectly
by suppressing IGFBP-1 thus increasing the sensitivity of
osteoblasts to IGF-1, then IGF-1 will modulate the actions of
PTH on bone leading to a synergistic eﬀect between insulin
and PTH as well an indirect synergistic eﬀect with other
substances that mediate anabolic eﬀects on bone [59, 60].
These are all theories, and more studies are needed to assess
the eﬀect of insulin on bone in male patients with diabetes.
7.Diabetic Complications
Uncontrolled diabetes with hyperglycemia has been suggest-
ed as a possible mechanism for osteoporosis in both type 1
and type2.This can occurbytheformation ofnonenzymatic
glycosylation of various bone proteins, including type 1 col-
lagen, leading to impaired bone quality [61]. There are
also some studies [62] associating high levels of pentosidine
to higher risk of fractures in diabetic patients. Moreover,
glucose is the principle source of energy for osteoclasts and
is able to increase avian osteoclast activity in vitro in a dose-
dependent manner [63]. Another indirect eﬀect of hyper-
glycemia on bone can be through hypercalciuria secondary
to glycosuria and other interactions with PTH and vitamin
D metabolism [64]. Some studies have shown that type 2
diabetes mellitus is associated with lower vitamin D levels
comparedtohealthycontrols[65,66].Despitethesetheories,
onlysome[67]butnotall[33,68]studieshavedemonstrated
that glycemiccontrol and HBA1Clevelswere associated with
osteoporosis in diabetic patients.
Otherthanglycemiccontrol,diabeticcomplicationswere
incriminated in osteoporosis, mainly retinopathy [69–71]b y
decreasing exercise thus leading to decreased muscle mass
and poor vision leading to increased incidence of falls,
nephropathy [70, 72, 73]b ya ﬀecting bone metabolism,
microangiopathy by directly aﬀecting bone vascularisation,
and neuropathy [74] by decreasing exercise. Yet again otherJournal of Osteoporosis 5
studies have shown contradictory results [28, 33]w i t hn o
association between either complication and BMD.
8.Bone Turnoverand Bone Stiffness
Most studies assessing bone turnover in diabetic patients
were limited by the small number of patients included. In
general, it was suggested that there is an imbalance between
bone formation and bone resorption in diabetes. Kemink
et al. reported a lower BMD in diabetic patients who con-
comitantly had lower alkaline phosphatase levels [34]. Dob-
nig et al. [75] showed that subjects with type 2 diabetes
mellitus had lower levels of PTH and osteocalcin. The same
was shown by Achemelal et al. [76] .T h u s ,i ts e e m st h a ti n
type 2DM, there is a decreased bone formation. This was
also shown by the study, previously mentioned above, by
Krakauer et al. [15], where they came up with a conclusion
that can explain the discrepancy between type 1 and type
2DM, that diabetes is accompanied by low bone formation
rate, that can lead to osteopenia in the growing skeleton,
whereas in type 2DM, there is low bone turnover that will
retard bone loss, explaining the increased bone density in
type 2DM. Another contradictory study, done by Alexop-
ulou et al. [27], showed that there was no diﬀerence in
osteocalcin levels or C-terminal telopeptide type 1 collagen
betweenmaleswithtype1diabetesmellitusandcontrols,but
osteoprotegerin was increased, showing contrary to previous
studies that bone formation was normal. In contrast to bone
formation, most studies [27, 75, 76]h a v es h o w nn o r m a l
bone resorption markers in diabetic patients, suggesting
with the associated low bone formation a state of low bone
turnover or adynamic bone in diabetes. Again this is just
a theory and more advanced studies are needed with more
assessment of bone markers for both bone formation and
resorption.
9.HormonalImbalance
Since hypogonadism in men was associated with low BMD
and fractures, and since most diabetic men have lower testo-
sterone levels when compared to nondiabetics, it was sug-
gested that diabetes can cause low BMD and higher risk
of fractures through causing hypogonadism. Studies on this
association are very limited, with one conducted by Asano
et al. [68]s h o w i n gaw e a kb u tas i g n i ﬁ c a n t l yp o s i t i v ec o r -
relation between serum bioavailable testosterone and bone
stiﬀness in type 2DM.
10.Conclusion
Both osteoporosis and diabetes are increasing in men.
Evidence of an association between both diseases is increas-
ing, but in face of the controversy and the limitation of
the studies done (small studies, cross-sectional, no clear
assessment of the pathophysiology), more studies correcting
for these limitations (with a longer followup, assessing
bone markers, hormonal factors, complications, shifting to
a better imaging, as CT&MRI instead of DXA assessment of
BMD)arestillneeded.Despitethefactthatspeciﬁcevidence-
based recommendations based on the present data are not
availableand cannotbemade,theremustbeawareness about
t h ef a c tt h a td i a b e t e s ,e s p e c i a l l yt y p e1 ,m i g h tb ear i s kf a c t o r
for osteoporosis, that it is multifactorial, possibly aﬀecting
cortical and trabecular bone diﬀerently. Speciﬁc measures
should be undertaken as encouraging exercise, assuring
adequatecalciumandvitaminDintake,andtreating diabetic
complications.
EvidenceAcquisition
The major source of data acquisition included Medline
search strategies, using the words “type 1 diabetes mellitus,”
“type 2 diabetes mellitus,” “osteoporosis,” and “men.” Arti-
cles published in the last 13 years were screened.
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